Coloplast revenue and financials
kr 418.80Change from previous close: +2.15%Absolute change: +kr 8.80
In the fiscal year ended September 2024, Coloplast reported revenue of kr 27.03B (+10.33% year over year). Net income was kr 5.05B, a net margin of 18.7%.
Fiscal year ending in September. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +10.33%
- FY to Sep 2024 vs FY to Sep 2023
- Net income growth
- +5.62%
- FY to Sep 2024 vs FY to Sep 2023
- Net margin
- 18.7%
- FY to Sep 2023: 19.5%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total revenue | 7,355 | 7,084 | 7,043 | 6,958 | 6,930 |
| Cost of revenue | 2,447 | 2,367 | 2,308 | 2,253 | 2,202 |
| Gross profit | 4,908 | 4,717 | 4,735 | 4,705 | 4,728 |
| Selling, general and administrative | 2,723 | 2,666 | 2,644 | 2,578 | 2,626 |
| Research and development | 281 | 254 | 247 | 239 | 239 |
| Operating income | 1,929 | 1,820 | 1,850 | 1,915 | 1,891 |
| EBIT | 2,080 | -1,056 | 1,955 | 1,832 | 1,807 |
| EBITDA | 2,443 | 2,293 | 2,300 | 2,175 | 2,151 |
| Interest expense | 206 | 188 | 164 | 490 | 316 |
| Pre-tax income | 1,874 | -1,244 | 1,791 | 1,342 | 1,491 |
| Income tax | 412 | -273 | 394 | 537 | 579 |
| Net income | 1,462 | -971 | 1,397 | 805 | 912 |
| Net income to common shareholders | 1,462 | -971 | 1,397 | 805 | 912 |
| Basic EPS | 6.49 | -4.31 | 6.20 | 3.57 | 4.05 |
| Diluted EPS | 6.49 | -4.31 | 6.20 | 3.57 | 4.05 |
| Average shares (basic) | 225 | 225 | 225 | 225 | 225 |
| Average shares (diluted) | 225 | 225 | 225 | 225 | 225 |